Biomarkers can help explain whether a treatment is engaging the intended biology, how the immune system is responding and whether changes in efficacy or safety are accompanied by measurable biological signals.

Pharmidex provides comprehensive cytokine analysis and biomarker profiling services across multiple therapeutic areas. Our multiplex capabilities generate precise, reliable quantitative data to support drug efficacy, safety, inflammation and immune-modulation studies from preclinical research through to clinical development.

• Multiplex cytokine profiling tailored to study objectives

• Analysis across plasma, serum, urine, BALF and tissue supernatant

• Mouse, rat and human biomarker panels

• Integration with pharmacology, flow cytometry, toxicology and regulatory bioanalysis

Pharmidex's cytokine analysis service supports multiple biological matrices, allowing biomarker strategies to be aligned with the tissue, compartment and biological response most relevant to the scientific question.

Plasma

Serum

Urine

BALF

Tissue Supernatant

Systemic cytokine and biomarker profiling across preclinical and clinical studies.

Quantitative analysis of circulating biomarkers and immune mediators.

Non-invasive matrix support for selected soluble biomarker endpoints.

Bronchoalveolar lavage fluid analysis for respiratory and inflammatory programmes.

Local tissue biomarker profiling to complement systemic readouts.

Pharmidex offers multiplex cytokine analysis with panels of up to 20 analytes, designed to study requirements. This allows related immune and inflammatory pathways to be evaluated together while making efficient use of valuable biological samples.

Published Pharmidex panels cover a broad range of chemokines, cytokines, growth factors, matrix-remodelling markers and immune-response proteins across mouse, rat and human studies.

Biomarker data become most valuable when they are selected around a clear biological hypothesis and interpreted alongside the other endpoints in the programme.

Drug Efficacy

Safety Assessment

Immune Modulation

Track biological changes associated with treatment response and add quantitative mechanistic evidence to efficacy endpoints.

Measure biomarker changes that can complement toxicology and clinical pathology findings and provide additional context around treatment effects.

Quantify cytokine and chemokine responses to understand how an intervention is affecting immune-cell signalling and inflammatory pathways.

Inflammation

Translational Research

Mechanism of Action

Profile inflammatory mediators across local and systemic matrices to investigate disease activity and pharmacodynamic response.

Use biomarker endpoints that can bridge preclinical and clinical programmes and support more connected interpretation across development stages.

Add pathway-relevant quantitative evidence that helps explain how a candidate is producing its observed biological or pharmacological effect.

Pharmidex publishes cytokine panels across mouse, rat and human samples, supporting biomarker strategies that can evolve as programmes move from experimental models towards clinical development.

Mouse

Rat

Human

Broad panels covering inflammatory, immune and tissue-response biomarkers commonly used across disease-model studies.

Multiplex support for cytokines, chemokines and other soluble biomarkers across pharmacology and safety studies.

Cytokine and chemokine profiling to support translational research, clinical studies and human biological sample analysis.

Pharmidex uses cytokine profiling across several of its established therapeutic research areas. This allows biomarker selection to be considered in the context of the disease model, pharmacological question and other endpoints being generated.

Use biomarker evidence alongside disease-model and pharmacological endpoints to build a clearer biological story.

Respiratory Disease

Autoimmune Disease

Metabolic Disorders

Toxicology

BALF and systemic cytokine profiling across inflammatory respiratory programmes.

Immune and inflammatory biomarkers supporting disease activity and treatment-response assessment.

Soluble biomarker analysis to add biological context to metabolic and inflammatory endpoints.

Biomarker profiling that can complement safety, clinical pathology and tissue findings.

Biomarker analysis can be combined with complementary Pharmidex capabilities to provide cellular, analytical, safety and regulatory context around the same programme.

Flow Cytometry

Regulatory Bioanalysis

Clinical Pathology

Preclinical Studies

Combine soluble cytokine data with immune-cell phenotype and functional cellular readouts for deeper immune-response analysis.

Pharmidex provides GLP/GCP-compliant regulatory bioanalysis covering PK, TK and biomarkers for preclinical and clinical development.

Add clinical chemistry and haematology endpoints to biomarker data where organ function, metabolic status or systemic safety are relevant.

Integrate biomarker endpoints into disease models, pharmacology, toxicology and other preclinical programmes.

Configure cytokine analysis around the species, matrices and biological pathways relevant to your study, with panels up to 20-plex.

Analyse circulating, local and tissue-derived samples including plasma, serum, urine, BALF and tissue supernatant.

Pharmidex combines multiplex cytokine analysis with broader bioanalytical, clinical and preclinical expertise, allowing biomarker programmes to be planned around the decisions they need to support.

Use biomarker profiling across mouse, rat and human programmes to support translational continuity as development advances.

Connect biomarker findings with flow cytometry, efficacy, toxicology, clinical pathology and regulatory bioanalysis where appropriate.

Common questions about Pharmidex's cytokine and biomarker analysis capabilities.

What biomarker analysis services does Pharmidex provide?

Pharmidex provides comprehensive cytokine and biomarker analysis to support drug discovery and development. The service focuses on quantitative multiplex cytokine profiling for efficacy, safety, inflammation, immune-modulation and translational studies across preclinical and clinical programmes.

Which sample matrices can Pharmidex analyse?

Pharmidex publishes biomarker capabilities across plasma, serum, urine, bronchoalveolar lavage fluid and tissue supernatant, allowing study-specific selection of systemic and local biological matrices.

How many cytokines can be analysed in a multiplex panel?

Pharmidex states that its multiplex cytokine panels can be designed up to 20-plex to specification. Available analytes vary by species and study requirements, and the team can be contacted where a required biomarker is not included in a published panel.

Does Pharmidex support mouse, rat and human biomarker analysis?

Yes. Pharmidex publishes multiplex cytokine panels for mouse, rat and human samples, supporting both preclinical studies and translational or clinical programmes.

Can biomarker analysis be combined with flow cytometry?

Yes. Pharmidex offers both biomarker analysis and high-throughput flow cytometry. Combining soluble cytokine measurements with immune-cell phenotype and functional readouts can provide complementary insight into immune modulation and pharmacological response.

Can Pharmidex support biomarkers in regulated studies?

Pharmidex provides GLP/GCP-compliant regulatory bioanalysis from MHRA-accredited laboratories, including biomarker analysis alongside PK and TK support for preclinical and clinical development.

Tell Pharmidex which biological response you need to understand, the matrices available and the stage of your programme. Our team can help define a cytokine or biomarker strategy aligned with your study objectives.

Contact Us

Address

167-169 Great Portland Street, Fifth Floor, London, W1W 5PF

Email: [email protected]